Page 17 - Robert Weinstein News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ADVERTISEMENT ADVERTISEMENT Weinstein Accusers' Appeal Says Ch. 11 Releases Improper Law360 (April 13, 2021, 7:11 PM EDT) -- Four rape and sexual assault accusers of disgraced film mogul Harvey Weinstein told a Delaware federal judge late Monday that the state's bankruptcy court had erred in confirming the Chapter 11 plan of Weinstein's former studio that included improper, nonconsensual releases that have hampered the accusers' ability to pursue their claims. In an appellate brief, the accusers said U.S. Bankruptcy Judge Mary F. Walrath should not have confirmed the Chapter 11 plan of The W...

Share this article Share this article WASHINGTON, March 15, 2021 /PRNewswire/ -- Fragrance Creators Association announced today Darci Ferrer has been promoted to Chief Scientist, overseeing the association's best-in-class regulatory science program advocating for greener chemistry, state-of-the-art fragrance technology and innovation, safety, and more. Through the organization's scientific programs and technical committees and task forces, Ferrer leads over 150 scientists, including thought leaders in the fields of environmental and human safety, research and development, regulatory affair...

Synaptogenix to Present at Upcoming Scientific Industry Conferences News provided by Share this article Share this article NEW YORK, Feb. 25, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it will attend two upcoming scientific industry conferences.   On Thursday, February 25 th, Dr. Daniel Alkon M.D., President and Chief Scientific Officer, will present a virtual poster at the 9 th annual Neurodegenerative Drug Development Summit. The virtual posters begin at 5...

New Study Demonstrates Bryostatin Normalizes Autistic Spectrum Behaviors in Mice - Peer Reviewed Article Published through Nature.com News provided by Share this article Share this article NEW YORK, Jan. 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), formerly Neurotrope Bioscience, Inc., announced a new report published by "Scientific Reports," an open-access journal publishing peer reviewed research through Nature.com, titled "Chronic Bryostatin-1 rescues autistic and cognitive phenotypes in the fragile X mice." This new study, in collaboration with the Fragile X Foundation and s...

Press release content from PR Newswire. The AP news staff was not involved in its creation. Synaptogenix Announces $14.0 Million Private Placement January 21, 2021 GMT NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Synaptogenix, Inc. (the “Company” or Synaptogenix) (OTCQX: SNPX), formerly Neurotrope Bioscience, Inc., announced today that it has entered into definitive securities purchase agreements with accredited investors to raise approximately $14.0 million in a private placement of common stock and warrants exercisable for common stock. In the private placement, the Company has agreed to sel...